News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Eli Lilly and Company’s Erbitux Fails In European Colon Cancer Study
October 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MILAN, Oct 10 (Reuters) - Two small European studies cast doubt on the benefits of two key bowel cancer drugs on Sunday, puzzling experts at Europe's biggest cancer meeting in Milan.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Eli Lilly and Company
MORE ON THIS TOPIC
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
·
3 min read
·
Heather McKenzie
Rare disease
Aardvark Tanks After Pausing Prader-Willi Study on ‘Surprise’ Safety Signals
March 2, 2026
·
2 min read
·
Tristan Manalac
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
March 2, 2026
·
2 min read
·
Tristan Manalac
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
February 26, 2026
·
1 min read
·
Jennifer Smith-Parker
